\
&
Contact us
\
&
Contact us
Published on | 5 months ago
ProgrammesPhortify - Photonics Education Network for Next-Gen Innovation and Digital Skills Excellence for Industry and Society has launched a number of cascade funding calls to support students and young professionals in the area of photonics:
More information about the different opportunities can be found via the links provided in the list above.
Participating Master programmes in Flemish universities are
Background:
Phortify is dedicated to the Enhancement and Harmonisation of Photonics education and training across Europe. Phortify offers a two-year European Master’s in Photonics Engineering, combining advanced coursework, hands-on laboratory training, and cutting-edge digital skills development, structured mobility windows and industry placements. Students who complete the Phortify track receive an official Phortify Certificate in addition to their Master’s degree. Students can enrol in a Phortify-related master programme at any of the 7 participating universities. In addition, Phortify provides stand-alone modules with harmonised standards for quality assurance and certification, offering high flexibility and mobility for both students and industry professionals. Finally, Phortify organises mentoring programmes for women postdocs and early PIs as well as one-day immersive experience events for prospective students, providing a unique opportunity to explore photonics and its applications.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
